Diamyd Medical AB - ESG Rating & Company Profile powered by AI
This assessment of Diamyd Medical AB is assembled by All Street Sevva using leading AI. Jump to the bottom of this page for potential risks for Diamyd Medical AB based on industry, location and marketcap. The page is a zero-cost Sustainability report covering Diamyd Medical AB.
Diamyd Medical AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 5.3, social score of 6.4 and governance score of 4.0.
5.2
Medium ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1725478325797)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
658 | Transchem Ltd | 5.3 | High |
658 | Zenith Healthcare Ltd | 5.3 | High |
687 | Diamyd Medical AB | 5.2 | High |
687 | Cardiol Therapeutics Inc | 5.2 | High |
687 | Cell Source Inc | 5.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1725478325797)
Frequently Asked Questions
Does Diamyd Medical AB have an accelerator or VC vehicle to help deliver innovation?
Does Diamyd Medical AB disclose current and historical energy intensity?
Does Diamyd Medical AB report the average age of the workforce?
Does Diamyd Medical AB reference operational or capital allocation in relation to climate change?
Does Diamyd Medical AB disclose its ethnicity pay gap?
Does Diamyd Medical AB disclose cybersecurity risks?
Does Diamyd Medical AB offer flexible work?
Does Diamyd Medical AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Diamyd Medical AB disclose the number of employees in R&D functions?
Does Diamyd Medical AB conduct supply chain audits?
Does Diamyd Medical AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Diamyd Medical AB conduct 360 degree staff reviews?
Does Diamyd Medical AB disclose the individual responsible for D&I?
Does Diamyd Medical AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Diamyd Medical AB disclose current and / or historical scope 2 emissions?
Does Diamyd Medical AB disclose water use targets?
Does Diamyd Medical AB have careers partnerships with academic institutions?
Did Diamyd Medical AB have a product recall in the last two years?
Does Diamyd Medical AB disclose incidents of discrimination?
Does Diamyd Medical AB allow for Work Councils/Collective Agreements to be formed?
Has Diamyd Medical AB issued a profit warning in the past 24 months?
Does Diamyd Medical AB disclose parental leave metrics?
Does Diamyd Medical AB disclose climate scenario or pathway analysis?
Does Diamyd Medical AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Diamyd Medical AB disclose the pay ratio of women to men?
Does Diamyd Medical AB support suppliers with sustainability related research and development?
Does Diamyd Medical AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Diamyd Medical AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Diamyd Medical AB involved in embryonic stem cell research?
Does Diamyd Medical AB disclose GHG and Air Emissions intensity?
Does Diamyd Medical AB disclose its waste policy?
Does Diamyd Medical AB report according to TCFD requirements?
Does Diamyd Medical AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Diamyd Medical AB disclose energy use targets?
Does Diamyd Medical AB disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Diamyd Medical AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Diamyd Medical AB
These potential risks are based on the size, segment and geographies of the company.
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.